Cite
Chuang CC, Guillemin I, Bachert C, et al. Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds. Laryngoscope. 2021;132(2):259-264doi: 10.1002/lary.29911.
Chuang, C. C., Guillemin, I., Bachert, C., Lee, S. E., Hellings, P. W., Fokkens, W. J., Duverger, N., Fan, C., Daizadeh, N., Amin, N., Mannent, L. P., Khan, A. H., & Kamat, S. (2022). Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds. The Laryngoscope, 132(2), 259-264. https://doi.org/10.1002/lary.29911
Chuang, Chien-Chia, et al. "Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds." The Laryngoscope vol. 132,2 (2022): 259-264. doi: https://doi.org/10.1002/lary.29911
Chuang CC, Guillemin I, Bachert C, Lee SE, Hellings PW, Fokkens WJ, Duverger N, Fan C, Daizadeh N, Amin N, Mannent LP, Khan AH, Kamat S. Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds. Laryngoscope. 2022 Feb;132(2):259-264. doi: 10.1002/lary.29911. Epub 2021 Nov 24. PMID: 34817082.
Copy
Download .nbib